{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T20:39:49Z","timestamp":1794602389442,"version":"4.9.1"},"reference-count":59,"publisher":"American Chemical Society (ACS)","issue":"9","license":[{"start":{"date-parts":[[2019,8,19]],"date-time":"2019-08-19T00:00:00Z","timestamp":1566172800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2019,8,19]],"date-time":"2019-08-19T00:00:00Z","timestamp":1566172800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2019,8,19]],"date-time":"2019-08-19T00:00:00Z","timestamp":1566172800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acc. Chem. Res."],"published-print":{"date-parts":[[2019,9,17]]},"DOI":"10.1021\/acs.accounts.9b00228","type":"journal-article","created":{"date-parts":[[2019,8,19]],"date-time":"2019-08-19T12:39:02Z","timestamp":1566218342000},"page":"2445-2461","source":"Crossref","is-referenced-by-count":599,"title":["Survey of Clinical Translation of Cancer Nanomedicines\u2014Lessons Learned from Successes and Failures"],"prefix":"10.1021","volume":"52","author":[{"given":"Hongliang","family":"He","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, 428 Church Street, Ann Arbor, Michigan 48109, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisha","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, 428 Church Street, Ann Arbor, Michigan 48109, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily E.","family":"Morin","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, 428 Church Street, Ann Arbor, Michigan 48109, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, School of Pharmacy, Fudan University, Shanghai 200032, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8023-8080","authenticated-orcid":true,"given":"Anna","family":"Schwendeman","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, 428 Church Street, Ann Arbor, Michigan 48109, United States"},{"name":"Biointerfaces Institute, NCRC Building, 2800 Plymouth Road, Ann Arbor, Michigan 48109, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2019,8,19]]},"reference":[{"key":"ref1\/cit1","unstructured":"Cancer Facts &\nFigures of 2018. https:\/\/www.cancer.org\/content\/dam\/cancer-org\/research\/cancer-facts-and-statistics\/annual-cancer-facts-and-figures\/2018\/cancer-facts-and-figures-2018.pdf (accessed July 1, 2019)."},{"key":"ref2\/cit2","doi-asserted-by":"publisher","DOI":"10.1038\/nnano.2007.387"},{"key":"ref3\/cit3","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3180"},{"key":"ref4\/cit4","doi-asserted-by":"publisher","DOI":"10.1021\/nn900002m"},{"key":"ref5\/cit5","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3003651"},{"key":"ref6\/cit6","doi-asserted-by":"publisher","DOI":"10.1021\/nn304474j"},{"key":"ref7\/cit7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0912273"},{"key":"ref8\/cit8","unstructured":"U.S. cancer doctors drop pricey drugs with little or no effect. https:\/\/www.reuters.com\/article\/us-usa-healthcare-cancer-insight\/u-s-cancer-doctors-drop-pricey-drugs-with-little-or-no-effect-idUSKCN0S20DG20151008 (accessed July 1, 2019)."},{"key":"ref9\/cit9","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.108"},{"key":"ref10\/cit10","doi-asserted-by":"publisher","DOI":"10.1038\/natrevmats.2016.14"},{"key":"ref11\/cit11","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2018.05.008"},{"key":"ref12\/cit12","doi-asserted-by":"publisher","DOI":"10.1002\/anie.200802585"},{"key":"ref13\/cit13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2011.06.001"},{"key":"ref14\/cit14","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.7b04855"},{"key":"ref15\/cit15","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-bioeng-071811-150124"},{"key":"ref16\/cit16","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2018.01.036"},{"key":"ref17\/cit17","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3377-3"},{"key":"ref18\/cit18","unstructured":"Pacira halts production of Depocyt. https:\/\/www.biopharmadive.com\/news\/pacira-depocyt-end-production-discontinue\/446507\/ (accessed July 1, 2019)."},{"key":"ref19\/cit19","unstructured":"Mirna Therapeutics\nHalts Phase 1 Clinical Study of MRX34. https:\/\/www.businesswire.com\/news\/home\/20160920006814\/en\/Mirna-Therapeutics-Halts-Phase-1-Clinical-Study (accessed July 1, 2019)."},{"key":"ref20\/cit20","unstructured":"Merrimack Discontinues\nDevelopment of MM-310. http:\/\/investors.merrimack.com\/news-releases\/news-release-details\/merrimack-discontinues-development-mm-310 (accessed July 1, 2019)."},{"key":"ref21\/cit21","doi-asserted-by":"publisher","DOI":"10.1021\/mp200394t"},{"key":"ref22\/cit22","first-page":"6387","volume":"46","author":"Matsumura Y.","year":"1986","journal-title":"Cancer Res."},{"key":"ref23\/cit23","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-4561"},{"key":"ref24\/cit24","doi-asserted-by":"publisher","DOI":"10.1021\/acs.bioconjchem.6b00437"},{"key":"ref25\/cit25","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.3330"},{"key":"ref26\/cit26","doi-asserted-by":"publisher","DOI":"10.1126\/science.1229568"},{"key":"ref27\/cit27","doi-asserted-by":"publisher","DOI":"10.1038\/nnano.2017.54"},{"key":"ref28\/cit28","doi-asserted-by":"publisher","DOI":"10.1038\/nnano.2012.212"},{"key":"ref29\/cit29","doi-asserted-by":"publisher","DOI":"10.1021\/acs.nanolett.8b01892"},{"key":"ref30\/cit30","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.2168"},{"key":"ref31\/cit31","doi-asserted-by":"publisher","DOI":"10.1038\/nature08956"},{"key":"ref32\/cit32","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2016.118"},{"key":"ref33\/cit33","doi-asserted-by":"publisher","DOI":"10.1186\/s40349-017-0104-0"},{"key":"ref34\/cit34","unstructured":"Bind Therapeutics\nlooks for big immuno-oncology partner as CEO mulls\nselling the company. https:\/\/www.fiercebiotech.com\/r-d\/bind-therapeutics-looks-for-big-immuno-oncology-partner-as-ceo-mulls-selling-company (accessed July 1, 2019)."},{"key":"ref35\/cit35","doi-asserted-by":"publisher","DOI":"10.1016\/j.cossms.2012.10.001"},{"key":"ref36\/cit36","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-0978"},{"key":"ref37\/cit37","unstructured":"Withdrawal Assessment Report for Opaxio. https:\/\/www.ema.europa.eu\/documents\/withdrawal-report\/withdrawal-assessment-report-opaxio_en.pdf (accessed July 1, 2019)."},{"key":"ref38\/cit38","unstructured":"KEI comment on the\nnew Tufts Study on Drug Development Costs. https:\/\/www.keionline.org\/22646 (accessed July 1, 2019)."},{"key":"ref39\/cit39","unstructured":"Does it really cost\n$2.6 billion to develop a new drug? https:\/\/www.washingtonpost.com\/news\/wonk\/wp\/2014\/11\/18\/does-it-really-cost-2-6-billion-to-develop-a-new-drug\/?utm_term=.0a51fbe37a59 (accessed July 1, 2018)."},{"key":"ref40\/cit40","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2018.3931"},{"key":"ref41\/cit41","unstructured":"The cost of cancer: new drugs show success\nat a steep price. https:\/\/www.reuters.com\/article\/us-usa-healthcare-cancer-costs\/the-cost-of-cancer-new-drugs-show-success-at-a-steep-price-idUSKBN1750FU (accessed July 1, 2019)."},{"key":"ref42\/cit42","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar4060"},{"key":"ref43\/cit43","doi-asserted-by":"publisher","DOI":"10.1038\/s41565-018-0273-1"},{"key":"ref44\/cit44","unstructured":"Nanomedicine\nMarket Size Worth $350.8 Billion By 2025. https:\/\/www.grandviewresearch.com\/press-release\/global-nanomedicine-market (accessed July 1, 2019)."},{"key":"ref45\/cit45","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.2.653"},{"key":"ref46\/cit46","unstructured":"Alza to buy Sequus $580 million deal to\nbolster development of new\ncancer drugs. https:\/\/www.sfgate.com\/business\/article\/Alza-to-buy-Sequus-580-million-deal-to-bolster-3066262.php (accessed July 1, 2019)."},{"key":"ref47\/cit47","unstructured":"Johnson & Johnson\nAnnounces Completion of Merger with ALZA Corporation. https:\/\/johnsonandjohnson.gcs-web.com\/news-releases\/news-release-details\/johnson-johnson-announces-completion-merger-alza-corporation (accessed July 1, 2019)."},{"key":"ref48\/cit48","unstructured":"United States Securities\nand Exchange Commission, 2015. https:\/\/www.sec.gov\/Archives\/edgar\/data\/1385228\/000156459016014829\/bind-10k_20151231.htm (accessed July 1, 2019)."},{"key":"ref49\/cit49","unstructured":"BIND Therapeutics\nAnnounces Completion of Collaboration Agreement\nwith Amgen. https:\/\/www.fiercebiotech.com\/biotech\/bind-therapeutics-announces-completion-of-collaboration-agreement-amgen (accessed July 1, 2019)."},{"key":"ref50\/cit50","unstructured":"Trouble brewing\nat Bind Therapeutics as major cuts announced. https:\/\/www.fiercebiotech.com\/r-d\/trouble-brewing-at-bind-therapeutics-as-major-cuts-announced (accessed July 1, 2019)."},{"key":"ref51\/cit51","unstructured":"Pfizer Wins Bid:\nBuys BIND Therapeutics Bankruptcy Assets for $40\nMillion. https:\/\/www.biospace.com\/article\/pfizer-wins-bid-buys-bind-therapeutics-bankruptcy-assets-for-40-million-\/ (accessed July 1, 2019)."},{"key":"ref52\/cit52","unstructured":"Merrimack Reports\nFourth Quarter and Full Year 2018 Financial Results. http:\/\/investors.merrimack.com\/news-releases\/news-release-details\/merrimack-reports-fourth-quarter-and-full-year-2018-financial (accessed July 1, 2019)."},{"key":"ref53\/cit53","unstructured":"Merrimack Stockholders\nApprove Sale of ONIVYDE\u00ae and Generic\nVersion of DOXIL\u00ae to Ipsen for Up to $1.025 Billion. http:\/\/investors.merrimack.com\/news-releases\/news-release-details\/merrimack-stockholders-approve-sale-onivyder-and-generic-version (accessed July 1, 2019)."},{"key":"ref54\/cit54","unstructured":"MM-302 Falls Short\nin Phase II HER2+ Breast Cancer Trial. https:\/\/www.onclive.com\/web-exclusives\/mm302-falls-short-in-phase-ii-her2-breast-cancer-trial (accessed July 1, 2019)."},{"key":"ref55\/cit55","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6112"},{"key":"ref56\/cit56","unstructured":"Oasmia Pharmaceutical Receives Approval\nfrom European Commission\nfor Apealea\u00ae (paclitaxel micellar) in the European Union. https:\/\/www.oasmia.com\/en\/oasmia-pharmaceutical-receives-approval-european-commission-apealea-paclitaxel-micellar-european-union\/ (accessed July 1, 2019)."},{"key":"ref57\/cit57","unstructured":"U.S. cancer institute\ncancels nanotech research centers. https:\/\/www.sciencemag.org\/news\/2019\/05\/us-cancer-institute-cancels-nanotech-research-centers (accessed July 1, 2019)."},{"key":"ref58\/cit58","doi-asserted-by":"publisher","DOI":"10.1126\/science.1226338"},{"key":"ref59\/cit59","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2017.131"}],"container-title":["Accounts of Chemical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.accounts.9b00228","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T00:56:11Z","timestamp":1681692971000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/doi\/10.1021\/acs.accounts.9b00228"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,19]]},"references-count":59,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9,17]]}},"alternative-id":["10.1021\/acs.accounts.9b00228"],"URL":"https:\/\/doi.org\/10.1021\/acs.accounts.9b00228","relation":{},"ISSN":["0001-4842","1520-4898"],"issn-type":[{"value":"0001-4842","type":"print"},{"value":"1520-4898","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,19]]}}}